2. Metabolic Enzyme/Protease MAPK/ERK Pathway PI3K/Akt/mTOR Stem Cell/Wnt Apoptosis Protein Tyrosine Kinase/RTK
  3. Endogenous Metabolite MAP3K Akt Mitochondrial Metabolism ERK Apoptosis ROS Kinase
  4. Phosphocreatine

Phosphocreatine  (Synonyms: Creatine phosphate; Creatinephosphoric acid)

Cat. No.: HY-D0885 Purity: ≥95.0%
SDS
COA
Handling Instructions Technical Support

Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..

For research use only. We do not sell to patients.

Phosphocreatine Chemical Structure

Phosphocreatine Chemical Structure

CAS No. : 67-07-2

Size Price Stock Quantity
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Phosphocreatine:

Phosphocreatine Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Phosphocreatine

View All MAP3K Isoform Specific Products:

View All Isoforms
MAP3K7/TAK1 MAP3K8 ASK2 MAP3K5/ASK1

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway.[1][2][3][4].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

Phosphocreatine (0-1 mM, 24 h) reveals the effect of anti-oxidant, anti-apoptosis and anti-necroptosis to protect agaist DOX (Doxorubicin) (HY-15142A)-induced cardiomyocytes injury in H9c2 cells by targeting TAK1[2].
Phosphocreatine (0-1 mM, 24 h) alleviates oxidative stress by increasing antioxidant activity, subsequently recovers expression level of TAK1 to baseline and reduces apoptosis and necroptosis in DOX-induced myocardial injury[2].
Phosphocreatine (5-20 mM, 24 h) attenuates cell injury and inhibits apoptosis induced by MGO (Methylglyoxal) (HY-106634) in PC12 cell[3].
Phosphocreatine (5-20 mM, 24 h) prevents loss of mitochondrial membrane permeability of MGO (Methylglyoxal) injured PC-12 cells[3].
Phosphocreatine (5-20 mM, 2 h) exhibits the neuroprotective effects in PC-12 cells relying on normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway[3].
Phosphocreatine (5-40 mM, 24 h) at different concentrations might contribute to protection of the NRK-52E cells against MGO-induced kidney injury[4].
Phosphocreatine (10-40 mM, 4 h) suppresses kidney oxidative stress metabolites[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Phosphocreatine Related Antibodies

Cell Viability Assay[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 0, 5, 10, 20, 40 mM
Incubation Time: 24 h
Result: Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (HY-106634) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Apoptosis Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 5, 10, 20, 40 mM
Incubation Time: 2 h
Result: Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells..
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells..
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells..
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Western Blot Analysis[3][4]

Cell Line: PC-12, NRK-52E cells
Concentration: 20, 40 mM
Incubation Time: 24 h
Result: Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
In Vivo

Phosphocreatine (200 mg/kg, i.p., once every other day, 7 weeks) not only alleviates oxidative stress and myocardial apoptosis, but also rescues myocardial necroptosis in DOX-induced cardiotoxicity of rat[2].
Phosphocreatine (20-40 mg/kg, i.v., daily, 6 weeks) has a protective effect on the kidney tissues against diabetic nephropathy in SD (Sprague Dawley) rats[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times [2].
Dosage: 200 mg/kg
Administration: i.p., once every other day, 7 weeks
Result: Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
Animal Model: Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (HY-13753)), daily, 6 weeks [4].
Dosage: 20, 40 mg/kg
Administration: i.p., daily, 6 weeks
Result: Reduced hyperglycemia compared with STZ (Streptozotocin) (HY-13753) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (HY-13753) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
Clinical Trial
Molecular Weight

211.11

Formula

C4H10N3O5P
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CN(C(NP(O)(O)=O)=N)C
Structure Classification
Initial Source

skeletal muscles of vertebrates
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : 175 mg/mL (828.95 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7369 mL 23.6843 mL 47.3687 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: ≥95.0%

SDS (393 KB)

COA (245 KB) HNMR (251 KB) CNMR (305 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 4.7369 mL 23.6843 mL 47.3687 mL 118.4217 mL
5 mM 0.9474 mL 4.7369 mL 9.4737 mL 23.6843 mL
10 mM 0.4737 mL 2.3684 mL 4.7369 mL 11.8422 mL
15 mM 0.3158 mL 1.5790 mL 3.1579 mL 7.8948 mL
20 mM 0.2368 mL 1.1842 mL 2.3684 mL 5.9211 mL
25 mM 0.1895 mL 0.9474 mL 1.8947 mL 4.7369 mL
30 mM 0.1579 mL 0.7895 mL 1.5790 mL 3.9474 mL
40 mM 0.1184 mL 0.5921 mL 1.1842 mL 2.9605 mL
50 mM 0.0947 mL 0.4737 mL 0.9474 mL 2.3684 mL
60 mM 0.0789 mL 0.3947 mL 0.7895 mL 1.9737 mL
80 mM 0.0592 mL 0.2961 mL 0.5921 mL 1.4803 mL
100 mM 0.0474 mL 0.2368 mL 0.4737 mL 1.1842 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Phosphocreatine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Phosphocreatine67-07-2Creatine Creatinephosphoric acidEndogenous MetaboliteMAP3KAktMitochondrial MetabolismERKApoptosisROS KinaseMAP kinase kinase kinase, MEKK, MAPKKKPKBProtein kinase BExtracellular signal regulated kinasesATPmuscle contractioncardiotoxicitymitochondrial functionoxidative stressInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Phosphocreatine
Cat. No.:
HY-D0885
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.